Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Working Capital to Net Assets Ratio
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Working Capital to Net Assets ratio of 59.8% as of March 2026. Working capital of CN¥758.31 Million (current assets of CN¥1.72 Billion minus current liabilities of CN¥962.47 Million) is measured against net assets of CN¥1.27 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Beijing Sun Novo Pharmaceutical Research (688621) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Beijing Sun Novo Pharmaceutical Research Co Ltd Working Capital to Net Assets (2017–2025)
This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the ratio stands at 59.8%, reflecting working capital of CN¥758.31 Million against net assets of CN¥1.27 Billion CNY. See 688621 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Beijing Sun Novo Pharmaceutical Research market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 62.6% | CN¥771.97 Million | CN¥1.23 Billion | CN¥1.74 Billion | CN¥968.65 Million | ▼ -4.2 pp |
| 2024 | 66.7% | CN¥735.93 Million | CN¥1.10 Billion | CN¥1.51 Billion | CN¥778.56 Million | ▲ +10.4 pp |
| 2023 | 56.4% | CN¥595.93 Million | CN¥1.06 Billion | CN¥1.36 Billion | CN¥761.21 Million | ▼ -1.1 pp |
| 2022 | 57.4% | CN¥521.77 Million | CN¥908.23 Million | CN¥1.04 Billion | CN¥518.19 Million | ▼ -10.6 pp |
| 2021 | 68.1% | CN¥523.96 Million | CN¥769.64 Million | CN¥941.79 Million | CN¥417.83 Million | ▲ +31.3 pp |
| 2020 | 36.8% | CN¥70.94 Million | CN¥192.92 Million | CN¥262.87 Million | CN¥191.94 Million | ▲ +24.3 pp |
| 2019 | 12.4% | CN¥14.77 Million | CN¥118.76 Million | CN¥181.53 Million | CN¥166.76 Million | ▲ +18.9 pp |
| 2018 | -6.4% | CN¥-4.74 Million | CN¥73.82 Million | CN¥119.07 Million | CN¥123.81 Million | ▲ +0.5 pp |
| 2017 | -6.9% | CN¥-2.31 Million | CN¥33.25 Million | CN¥65.78 Million | CN¥68.08 Million | — |